Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Vancomycin remains the reference standard for the treatment of systemic infection caused by methicillin-resistant Staphylococcus aureus (MRSA). However, as a result of limited tissue distribution, as well as the emergence of isolates with reduced susceptibility and in vitro resistance to vancomycin, the need for alternative therapies that target MRSA has become apparent. New treatment options for invasive MRSA infections include linezolid, daptomycin, tigecycline, and quinupristin/dalfopristin. Additionally, a number of new anti-MRSA compounds are in development, including novel glycopeptides (dalbavancin, telavancin, and oritavancin), ceftobiprole, and iclaprim. The present article will review clinical issues surrounding the newly marketed and investigational agents with activity against MRSA.
Micek
Scott T
ST
Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, USA. stm8241@bjc.org
D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D016106:Methicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000737:chemistry / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D014640:Vancomycin